Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04314531 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04314531 · ClinicalTrials.gov record · last posted 2026-03-10

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

StatusActive, Not Recruiting
PhasePhase 3
Started2020-07-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .

Amendment record 33 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 33 times since 2020-03-17; most recent amendment 2026-04-17. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-04-17
Status change Active, Not Recruiting→Completedv33
2024-03-01
Status change Recruiting→Active, Not Recruitingv23
2020-07-03
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT04314531
Lead Sponsor Sun Pharmaceutical Industries Limited
Conditions Active Psoriatic Arthritis
Enrollment 296 participants
Start Date 2020-07-01
Primary Completion 2025-06-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-10